Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.

Eleftherios P P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K L Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker R Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Schnabel Norman Wolmark

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

BCI (H/I)-High versus BCI (H/I)-Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4 years, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.

Keyphrases